Literature DB >> 23434419

Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.

Royce A Wilkinson1, Seth H Pincus, Kejing Song, Joyce B Shepard, Alan J Weaver, Mohamed E Labib, Martin Teintze.   

Abstract

The G-protein coupled receptor CXCR4 is a co-receptor for HIV-1 infection and is involved in signaling cell migration and proliferation. In a previous study of non-peptide, guanide-based CXCR4-binding compounds, spermine and spermidine phenylguanides inhibited HIV-1 entry at low micromolar concentrations. Subsequently, crystal structures of CXCR4 were used to dock a series of naphthylguanide derivatives of the polyamines spermidine and spermine. Synthesis and evaluation of the naphthylguanide compounds identified our best compound, spermine tris-1-naphthylguanide, which bound CXCR4 with an IC(50) of 40 nM and inhibited the infection of TZM-bl cells with X4, but not R5, strains of HIV-1 with an IC(50) of 50-100 nM.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434419      PMCID: PMC3624624          DOI: 10.1016/j.bmcl.2013.01.107

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

1.  Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries.

Authors:  Nobutaka Fujii; Shinya Oishi; Kenichi Hiramatsu; Takanobu Araki; Satoshi Ueda; Hirokazu Tamamura; Akira Otaka; Shuichi Kusano; Shigemi Terakubo; Hideki Nakashima; James A Broach; John O Trent; Zi-xuan Wang; Stephen C Peiper
Journal:  Angew Chem Int Ed Engl       Date:  2003-07-21       Impact factor: 15.336

2.  Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule.

Authors:  D E McCallus; K E Ugen; A I Sato; W V Williams; D B Weiner
Journal:  Viral Immunol       Date:  1992       Impact factor: 2.257

3.  Involvement of chemokine receptors in breast cancer metastasis.

Authors:  A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

4.  Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes.

Authors:  J Louwagie; E L Delwart; J I Mullins; F E McCutchan; G Eddy; D S Burke
Journal:  AIDS Res Hum Retroviruses       Date:  1994-05       Impact factor: 2.205

5.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Antigenically distinct conformations of CXCR4.

Authors:  F Baribaud; T G Edwards; M Sharron; A Brelot; N Heveker; K Price; F Mortari; M Alizon; M Tsang; R W Doms
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.

Authors:  Royce A Wilkinson; Seth H Pincus; Joyce B Shepard; Sarah K Walton; Edward P Bergin; Mohamed Labib; Martin Teintze
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

8.  Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.

Authors:  H Tamamura; A Omagari; S Oishi; T Kanamoto; N Yamamoto; S C Peiper; H Nakashima; A Otaka; N Fujii
Journal:  Bioorg Med Chem Lett       Date:  2000-12-04       Impact factor: 2.823

9.  Immunological characteristics associated with the protective efficacy of antibodies to ricin.

Authors:  Massimo Maddaloni; Corrie Cooke; Royce Wilkinson; Audrey V Stout; Leta Eng; Seth H Pincus
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives.

Authors:  Hirokazu Tamamura; Kenichi Hiramatsu; a Shuichi Kusano; Shigemi Terakubo; Naoki Yamamoto; John O Trent; Zixuan Wang; Stephen C Peiper; Hideki Nakashima; Akira Otaka; Nobutaka Fujii
Journal:  Org Biomol Chem       Date:  2003-11-07       Impact factor: 3.876

View more
  6 in total

Review 1.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  Structural Analysis of Chemokine Receptor-Ligand Interactions.

Authors:  Marta Arimont; Shan-Liang Sun; Rob Leurs; Martine Smit; Iwan J P de Esch; Chris de Graaf
Journal:  J Med Chem       Date:  2017-03-10       Impact factor: 7.446

3.  Predicting target-ligand interactions with graph convolutional networks for interpretable pharmaceutical discovery.

Authors:  Paola Ruiz Puentes; Laura Rueda-Gensini; Natalia Valderrama; Isabela Hernández; Cristina González; Laura Daza; Carolina Muñoz-Camargo; Juan C Cruz; Pablo Arbeláez
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

4.  Antibacterial activity of THAM Trisphenylguanide against methicillin-resistant Staphylococcus aureus.

Authors:  Alan J Weaver; Joyce B Shepard; Royce A Wilkinson; Robert L Watkins; Sarah K Walton; Amanda R Radke; Thomas J Wright; Milat B Awel; Catherine Cooper; Elizabeth Erikson; Mohamed E Labib; Jovanka M Voyich; Martin Teintze
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

5.  Multi-objective active machine learning rapidly improves structure-activity models and reveals new protein-protein interaction inhibitors.

Authors:  D Reker; P Schneider; G Schneider
Journal:  Chem Sci       Date:  2016-03-10       Impact factor: 9.825

6.  Exposure of Methicillin-Resistant Staphylococcus aureus to Low Levels of the Antibacterial THAM-3ΦG Generates a Small Colony Drug-Resistant Phenotype.

Authors:  Alan J Weaver; Tami R Peters; Brian Tripet; Abigail Van Vuren; Richard E Lee; Valérie Copié; Martin Teintze
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.